- •Approximately 9–24% of cases of epithelial ovarian cancer are due to germline mutations in BRCA1 and BRCA2.
- •For a woman with BRCA1-2 mutations the risk to develop an ovarian/fallopian tube cancer is 39–46% and 10–27%, respectively.
- •STIC is currently considered the precursor lesion of pelvic ovarian/peritoneal high-grade serous carcinoma
- •The rate of PPC after diagnosis of STIC is 4.5-6% in high-risk patients.
- •The role of subsequent surgery or chemotherapy or strict follow-up to preventing PPC in patients with STIC remains unclear.
Serous tubal intraepithelial carcinoma (STIC) is currently considered the precursor lesion of pelvic high-grade serous carcinoma. The management of STIC diagnosed after risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA1–2 variants remains unclear. The aim of our study was to evaluate the incidence of STIC, serous tubal intraepithelial lesions (STIL) and occult invasive cancer (OC) and to determine the long-term outcomes of these patients.
We conducted a retrospective study of patients with BRCA 1–2 variants who underwent RRSO between January-2010 and Dicember-2020 at the Clinic of Gynaecology of University of Padova. Inclusion criteria: women with a negative pelvic examination at the last screening prior to RRSO, patients with fallopian tubes analysed using the SEE-FIM protocol. Exclusion criteria: patients with a positive gynaecologic screening or with ovarian/tubal cancer prior to RRSO.
We included 153 patients. STICs were diagnosed in 4 patients (2.6%) and STILs in 6 patients (3.9%). None of the patients with STIC underwent restaging surgery or adjuvant chemotherapy; all patients were followed closely every 6 months. None of the patients developed primary peritoneal carcinomas (PPCs) with a median FUP of 54.5 months (15–106). OC was diagnosed in 3 patients (2%). All patients with OC underwent staging surgery, and one patient developed a peritoneal carcinoma (PC) after 18 months by staging surgery.
The incidence of STIC, STIL and OC after RRSO in BRCA1–2 variants was low. Our results demonstrated that long-term close surveillance in patients diagnosed with STIC should be considered a possible management strategy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Gynecologic Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.Int. J. Cancer. 2015; 136: 359-386https://doi.org/10.1002/ijc.29210
- Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.Science. 2003; 302: 643-646https://doi.org/10.1126/science.1088759
- The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.N. Engl. J. Med. 1997; 336: 1401-1408https://doi.org/10.1056/NEJM199705153362001
- Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.J. Natl. Cancer Inst. 2002; 94: 1365-1372https://doi.org/10.1093/jnci/94.18.1365
- Meta-analysis of BRCA1 and BRCA2 penetrance.J. Clin. Oncol. 2007; 25: 1329-1333https://doi.org/10.1200/JCO.2006.09.1066
- Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.Am. J. Hum. Genet. 2003; 72: 1117-1130https://doi.org/10.1086/375033
- Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.Am. J. Hum. Genet. 1998; 62: 676-689https://doi.org/10.1086/301749
- National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian.J. Natl. Compr. Cancer Netw. 2010; 8: 562-594https://doi.org/10.6004/jnccn.2010.0043
- Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.N. Engl. J. Med. 2002; 346: 1616-1622https://doi.org/10.1056/NEJMoa012158
- Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.Gynecol. Oncol. 2005; 97: 457-467https://doi.org/10.1016/j.ygyno.2005.01.039
- Management of Preinvasive Lesions.Clin. Obstet. Gynecol. 2017; 60: 771-779https://doi.org/10.1097/GRF.0000000000000316
- The distal fallopian tube: a new model for pelvic serous carcinogenesis.Curr. Opin. Obstet. Gynecol. 2007; 19: 3-9https://doi.org/10.1097/GCO.0b013e328011a21f
- Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC).Int. J. Gynecol. Cancer. 2013; 23: 1603-1611https://doi.org/10.1097/IGC.0b013e3182a80ac8
- Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review.Gynecol. Oncol. 2015; 139: 568-572https://doi.org/10.1016/j.ygyno.2015.09.018
- Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.Breast Cancer Res. Treat. 2010; 124: 195-203https://doi.org/10.1007/s10549-010-0799-x
- Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.Gynecol. Oncol. 2012; 127: 88-93https://doi.org/10.1016/j.ygyno.2012.06.015
- Staging classification for cancer of the ovary, fallopian tube, and peritoneum.Int. J. Gynaecol. Obstet. 2014; 124: 1-5https://doi.org/10.1016/j.ijgo.2013.10.001
- High-grade serous carcinoma of the fallopian tube.in: WHO Classification Tumors- Female Genital Tumors. 5th ed. IARC, 2002
- Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.Ann. Surg. 2004; 240: 205-213https://doi.org/10.1097/01.sla.0000133083.54934.ae
- Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary.Gynecol. Oncol. 1993; 50 (PMID: 8406199): 347-351https://doi.org/10.1006/gyno.1993.1223
- Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.Nat. Rev. Clin. Oncol. 2017; 14: 284-296https://doi.org/10.1038/nrclinonc.2016.191
- The fallopian tube as origin of ovarian cancer: change of diagnostic and preventive strategies.Cancer Med. 2020; 9: 421-431https://doi.org/10.1002/cam4.2725
- Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.Clin. Med. Res. 2007; 5: 35-44https://doi.org/10.3121/cmr.2007.702
- High-grade serous ovarian cancer arises from fallopian tube in a mouse model.Proc. Natl. Acad. Sci. U. S. A. 2012; 109: 3921-3926https://doi.org/10.1073/pnas.1117135109
- Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies:a study of 300 consecutive cases.Int. J. Gynecol. Pathol. 2012; 31: 103-110https://doi.org/10.1097/PGP.0b013e31822ea955
- Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis.Int. J. Clin. Exp. Pathol. 2014; 7: 848-857
- Outcome and prognostic impact of surgical staging in serous tubal intraepithelial carcinoma: a cohort study and systematic review.Oncol. (R. Coll. Radiol.). 2018; 30: 463-471https://doi.org/10.1016/j.clon.2018.03.036
- Risk-reducing Salpingo-Oophorectomy in women at higher risk of ovarian and breast cancer: a single institution prospective series.Anticancer Res. 2017; 37: 5241-5248https://doi.org/10.21873/anticanres.11948
- Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.Clin. Transl. Oncol. 2018; 20: 1337-1344https://doi.org/10.1007/s12094-018-1865-9
- Riskreducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical–pathological protocol.Int. J. Gynecol. Cancer. 2011; 21: 846-851https://doi.org/10.1097/IGC.0b013e31821bc7e3
- Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingooophorectomy.Gynecol. Oncol. 2013; 129: 364-371https://doi.org/10.1016/j.ygyno.2013.01.029
- Development of peritoneal carcinoma in women diagnosed with serous tubal intraepithelial carcinoma (STIC) following risk-reducing Salpingo-oophorectomy (RRSO).J. Ovarian Res. 2019; 25: 50https://doi.org/10.1186/s13048-019-0525-1
- Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.Expert. Rev. Anticancer. Ther. 2016; 16: 1311-1321https://doi.org/10.1080/14737140.2016.1247699
- Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.JAMA. 2006; 296: 185-192https://doi.org/10.1001/jama.296.2.185
- Occult and subsequent cancer incidence following riskreducing surgery in BRCA mutation carriers.Gynecol. Oncol. 2016; 143: 231-235https://doi.org/10.1016/j.ygyno.2016.08.336
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.Int. J. Gynecol. Cancer. 2019; https://doi.org/10.1136/ijgc-2019-000308
- Utility of peritoneal lavage cytology during laparoscopic salpingo-oophorectomy: a retrospective analysis.Br. J. Obstet. Gynaecol. 2011; 118: 28-33https://doi.org/10.1111/j.1471-0528.2010.02768.x
- The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.BMC Cancer. 2016; 1: 16-18https://doi.org/10.1186/s12885-015-2011-5
- Uterine Cancer after risk-reducing Salpingo-oophorectomy without hysterectomy in women with BRCA mutations.JAMA Oncol. 2016 Nov 1; 2: 1434-1440https://doi.org/10.1001/jamaoncol.2016.1820
Published online: August 28, 2021
Accepted: August 23, 2021
Received in revised form: August 20, 2021
Received: March 18, 2021
© 2021 Elsevier Inc. All rights reserved.